Form 4: MANGOCEUTICALS CFO Sells 10,000 Shares

MANGOCEUTICALS CFO Eugene M Johnston sold 10,000 shares of common stock on December 5, 2025, for a weighted average price of $1.128 per share.

Summary

• Eugene M Johnston, the Chief Financial Officer (CFO) of MANGOCEUTICALS, INC. (MGRX), reported a transaction involving the sale of common stock.
• The transaction occurred on December 5, 2025.
• A total of 10,000 shares of common stock were disposed of.
• The shares were sold at a weighted average price of $1.128 per share, with individual trades ranging from $1.10 to $1.20.
• Following this transaction, Mr. Johnston beneficially owns 128,333 shares of MANGOCEUTICALS common stock.

Sentiment

Score: 4

Explanation: The CFO's sale of 10,000 shares, while not a massive amount relative to total holdings, is generally viewed as a slight negative signal by the market, as it represents an insider reducing their stake.

Negatives

• An insider (CFO) sold 10,000 shares of common stock.
• Insider selling can sometimes be interpreted by the market as a signal of reduced confidence in the company's short-term prospects.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Sale of 10,000 shares of common stock by Eugene M Johnston, CFO, to the open market.

Stakeholder Impact

• Shareholders may interpret the insider sale as a signal regarding management's confidence in the company's future performance, potentially influencing investment decisions.

Next Steps

• The Reporting Person undertakes to provide full information regarding the number of shares and prices at which the transaction was effected upon request to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer.

Key Dates

Recommendation

While the CFO's sale of 10,000 shares is a notable insider transaction, it represents a relatively small portion of their total beneficial ownership (128,333 shares remaining). Without additional context on the reason for the sale (e.g., personal liquidity, diversification), it's prudent to maintain a 'hold' position and monitor future insider activity and company performance rather than making a definitive 'buy' or 'sell' decision based solely on this single transaction.

Keywords

MANGOCEUTICALS, MGRX, Insider Sale, Form 4, CFO, Stock Transaction, Eugene M Johnston